APA (7th ed.) Citation

Manuel, C. A., Rold, T. L., Sieckman, G. L., Szczodroski, A. F., & Hoffman, T. J. (2011). Abstract 3264: Preclinical multi-modal therapy of metastatic androgen independent prostate cancer using docetaxel, capecitabine, and a Lu-177-BB2r targeting peptide. Cancer research (Chicago, Ill.), 71(8_Supplement), 3264. https://doi.org/10.1158/1538-7445.AM2011-3264

Chicago Style (17th ed.) Citation

Manuel, Christopher A., Tammy L. Rold, Gary L. Sieckman, Ashley F. Szczodroski, and Timothy J. Hoffman. "Abstract 3264: Preclinical Multi-modal Therapy of Metastatic Androgen Independent Prostate Cancer Using Docetaxel, Capecitabine, and a Lu-177-BB2r Targeting Peptide." Cancer Research (Chicago, Ill.) 71, no. 8_Supplement (2011): 3264. https://doi.org/10.1158/1538-7445.AM2011-3264.

MLA (9th ed.) Citation

Manuel, Christopher A., et al. "Abstract 3264: Preclinical Multi-modal Therapy of Metastatic Androgen Independent Prostate Cancer Using Docetaxel, Capecitabine, and a Lu-177-BB2r Targeting Peptide." Cancer Research (Chicago, Ill.), vol. 71, no. 8_Supplement, 2011, p. 3264, https://doi.org/10.1158/1538-7445.AM2011-3264.